Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
29
06
2023
accepted:
28
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
epublish
Résumé
Treatment of Mycobacterium avium complex pulmonary disease (MAC-PD) involves prolonged courses of multiple antibiotics that are variably tolerated and commonly cause adverse drug reactions (ADR). The purpose of this retrospective, single-center study was to identify demographic and disease-related variables associated with significant ADRs among patients treated with antibiotics against MAC-PD. We reviewed all patients treated with antibiotic therapy for MAC-PD at a single center from 2000 to 2021. Patients were included if they met diagnostic criteria for MAC-PD, were prescribed targeted antibiotic therapy for any length of time and had their treatment course documented in their health record. We compared patients who completed antibiotics as originally prescribed (tolerant) with those whose antibiotic treatment course was modified or terminated secondary to an ADR (intolerant). Over the study period, 235 patients were prescribed antibiotic treatment with their clinical course documented in our center's electronic health record, and 246 treatment courses were analyzed. One hundred forty-three (57%) tolerated therapy versus 108 (43%) experienced ADRs. Among the 108 intolerant courses, 67 (63%) required treatment modification and 49 (46%) required premature treatment termination. Treatment intolerance was associated more frequently with smear positive sputum cultures (34% vs. 20%, p = 0.009), a higher Charlson Comorbidity Index (CCI) (4 vs. 6, p = 0.007), and existing liver disease (7% vs. 1%, p = 0.03). There was no between-group difference in BMI (21 vs. 22), fibrocavitary disease (24 vs. 19%), or macrolide sensitivity (94 vs. 80%). The use of daily therapy was not associated with intolerance (77 vs. 79%). Intolerant patients were more likely to be culture positive after 6 months of treatment (44 vs. 25%). Patients prescribed antibiotic therapy for MAC-PD are more likely to experience ADRs if they have smear positive sputum cultures at diagnosis, a higher CCI, or existing liver disease. Our study's rate of early treatment cessation due to ADR's was similar to that of other studies (20%) but is the first of its kind to evaluate patient and disease factors associated with ADR's. A systematic approach to classifying and addressing ADRs for patients undergoing treatment for MAC-PD is an area for further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of Mycobacterium avium complex pulmonary disease (MAC-PD) involves prolonged courses of multiple antibiotics that are variably tolerated and commonly cause adverse drug reactions (ADR). The purpose of this retrospective, single-center study was to identify demographic and disease-related variables associated with significant ADRs among patients treated with antibiotics against MAC-PD.
METHODS
METHODS
We reviewed all patients treated with antibiotic therapy for MAC-PD at a single center from 2000 to 2021. Patients were included if they met diagnostic criteria for MAC-PD, were prescribed targeted antibiotic therapy for any length of time and had their treatment course documented in their health record. We compared patients who completed antibiotics as originally prescribed (tolerant) with those whose antibiotic treatment course was modified or terminated secondary to an ADR (intolerant).
RESULTS
RESULTS
Over the study period, 235 patients were prescribed antibiotic treatment with their clinical course documented in our center's electronic health record, and 246 treatment courses were analyzed. One hundred forty-three (57%) tolerated therapy versus 108 (43%) experienced ADRs. Among the 108 intolerant courses, 67 (63%) required treatment modification and 49 (46%) required premature treatment termination. Treatment intolerance was associated more frequently with smear positive sputum cultures (34% vs. 20%, p = 0.009), a higher Charlson Comorbidity Index (CCI) (4 vs. 6, p = 0.007), and existing liver disease (7% vs. 1%, p = 0.03). There was no between-group difference in BMI (21 vs. 22), fibrocavitary disease (24 vs. 19%), or macrolide sensitivity (94 vs. 80%). The use of daily therapy was not associated with intolerance (77 vs. 79%). Intolerant patients were more likely to be culture positive after 6 months of treatment (44 vs. 25%).
CONCLUSIONS
CONCLUSIONS
Patients prescribed antibiotic therapy for MAC-PD are more likely to experience ADRs if they have smear positive sputum cultures at diagnosis, a higher CCI, or existing liver disease. Our study's rate of early treatment cessation due to ADR's was similar to that of other studies (20%) but is the first of its kind to evaluate patient and disease factors associated with ADR's. A systematic approach to classifying and addressing ADRs for patients undergoing treatment for MAC-PD is an area for further investigation.
Identifiants
pubmed: 38468274
doi: 10.1186/s12931-024-02752-y
pii: 10.1186/s12931-024-02752-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2024. The Author(s).
Références
Hoefsloot W, van Ingen J, Andrejak C, Ängeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–13.
doi: 10.1183/09031936.00149212
pubmed: 23598956
Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of Nontuberculous Mycobacterial Lung Disease in a large U.S. Managed Care Health Plan, 2008–2015. Ann Am Thorac Soc. 2020;17(2):178–85.
doi: 10.1513/AnnalsATS.201804-236OC
pubmed: 31830805
pmcid: 6993793
Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011;105(11):1718–25.
doi: 10.1016/j.rmed.2011.08.004
pubmed: 21868209
Maekawa K, Ito Y, Oga T, Hirai T, Kubo T, Fujita K, et al. High-resolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tuberc Lung Dis. 2013;17(6):829–35.
doi: 10.5588/ijtld.12.0672
pubmed: 23676171
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71(4):905–13.
doi: 10.1093/cid/ciaa1125
pubmed: 32797222
pmcid: 7768745
Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, et al. Efficacy of Clarithromycin and Ethambutol for Mycobacterium avium Complex Pulmonary Disease. A preliminary study. Ann Am Thorac Soc. 2014;11(1):23–9.
doi: 10.1513/AnnalsATS.201308-266OC
pubmed: 24298907
Griffith DE, Brown BA, Girard WM, Wallace RJ. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis off Publ Infect Dis Soc Am. 1995;21(3):594–8.
doi: 10.1093/clinids/21.3.594
Wallace RJ, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, et al. Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung Disease. Chest. 2014;146(2):276–82.
doi: 10.1378/chest.13-2538
pubmed: 24457542
pmcid: 4694082
Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ. Ethambutol Ocular toxicity in treatment regimens for Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2005;172(2):250–3.
doi: 10.1164/rccm.200407-863OC
pubmed: 15860751
Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium Complex Lung Disease. Clin Infect Dis. 2001;32(11):1547–53.
doi: 10.1086/320512
pubmed: 11340525
Kamii Y, Nagai H, Kawashima M, Matsuki M, Nagoshi S, Sato A, et al. Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2018;22(12):1505–10.
doi: 10.5588/ijtld.18.0171
pubmed: 30606324
Ozawa T, Namkoong H, Takaya R, Takahashi Y, Fukunaga K, Enoki Y, et al. Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system. BMC Infect Dis. 2022;22:580.
doi: 10.1186/s12879-022-07568-z
pubmed: 35768763
pmcid: 9241207
Wallace RJ, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 1993;16(3):215–21.
doi: 10.1016/0732-8893(93)90112-K
pubmed: 8477575
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: diagnosis, treatment, and Prevention of Nontuberculous Mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
doi: 10.1164/rccm.200604-571ST
pubmed: 17277290
Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. Long-term follow-up of Mycobacterium avium Complex Lung Disease in patients treated with regimens including clofazimine and/or Rifampin. Chest. 2016;149(5):1285–93.
doi: 10.1378/chest.15-0543
pubmed: 26513209
Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63(7):627–34.
doi: 10.1136/thx.2007.087999
pubmed: 18250184
Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017;50(3):1602503.
doi: 10.1183/13993003.02503-2016
pubmed: 28954780
Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004;126(2):566–81.
doi: 10.1378/chest.126.2.566
pubmed: 15302746
Pan SW, Shu CC, Feng JY, Wang JY, Chan YJ, Yu CJ, et al. Microbiological persistence in patients with Mycobacterium avium Complex Lung Disease: the predictors and the impact on Radiographic Progression. Clin Infect Dis. 2017;65(6):927–34.
doi: 10.1093/cid/cix479
pubmed: 28541556
Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017 Mar 1 [cited 2023 Jan 13];49(3). Available from: https://erj.ersjournals.com/content/49/3/1600537 .
Brown BA, Griffith DE, Girard W, Levin J, Wallace RJ. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis off Publ Infect Dis Soc Am. 1997;24(5):958–64.
doi: 10.1093/clinids/24.5.958
Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis. 2012;16(3):408–14.
doi: 10.5588/ijtld.11.0148
pubmed: 22230733
Asakura T, Funatsu Y, Ishii M, Namkoong H, Yagi K, Suzuki S, et al. Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients. Respir Res. 2015;16:145.
doi: 10.1186/s12931-015-0304-5
pubmed: 26635226
pmcid: 4668618
Ku JH, Henkle E, Carlson KF, Marino M, Brode SK, Marras TK et al. Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA guidelines. Clin Infect Dis. 2022;ciac394.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin Liposome Inhalation suspension for treatment-refractory lung Disease caused by Mycobacterium avium Complex (CONVERT). A prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018;198(12):1559–69.
doi: 10.1164/rccm.201807-1318OC
pubmed: 30216086
Winthrop K. Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease. clinicaltrials.gov; 2023 Dec [cited 2023 Dec 31]. Report No.: NCT03672630. Available from: https://clinicaltrials.gov/study/NCT03672630 .
Gochi M, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015;5(8):e008058.
doi: 10.1136/bmjopen-2015-008058
pubmed: 26246077
pmcid: 4538251
Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-Negative patients with Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2012;185(5):575–83.
doi: 10.1164/rccm.201107-1203OC
pubmed: 22199005
Kim HJ, Kwak N, Hong H, Kang N, Im Y, Jhun BW, et al. BACES score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease. Am J Respir Crit Care Med. 2021;203(2):230–6.
doi: 10.1164/rccm.202004-1418OC
pubmed: 32721164
Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2015;191(1):96–103.
doi: 10.1164/rccm.201408-1545OC
pubmed: 25393520
Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1766–72.
doi: 10.1164/ajrccm.153.6.8665032
pubmed: 8665032
Griffith DE, Aksamit TR. Managing Mycobacterium avium Complex Lung Disease with a little help from my friend. Chest. 2021;159(4):1372–81.
doi: 10.1016/j.chest.2020.10.031
pubmed: 33080299